Literature DB >> 16005694

High throughput assay for the determination of lumefantrine in plasma.

A Annerberg1, T Singtoroj, P Tipmanee, N J White, N P J Day, N Lindegårdh.   

Abstract

A high throughput bioanalytical assay for the determination of lumefantrine in plasma has been developed and validated extensively. The within-day precisions for lumefantrine were 5.2, 3.5 and 2.5% at 200, 2000 and 15000 ng/mL, respectively. The between-day precisions were 4.0, 2.8 and 3.1% at 200, 2000 and 15000 ng/mL, respectively. The lower limits of quantification (LLOQ) and the limits of detection (LOD) were 25 and 10 ng/mL, respectively using 0.250 mL plasma. The average recovery of lumefantrine was 85% and independent upon concentration. The use of 96-well plate format and short chromatographic run has increased the daily sample throughput four times. The assay is particularly suitable for large therapeutic drug monitoring studies using day 7 sampling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005694     DOI: 10.1016/j.jchromb.2005.06.022

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  14 in total

1.  Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.

Authors:  Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

2.  Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation.

Authors:  Liusheng Huang; Xiaohua Li; Florence Marzan; Patricia S Lizak; Francesca T Aweeka
Journal:  Bioanalysis       Date:  2012-01       Impact factor: 2.681

3.  Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.

Authors:  Sofia Friberg Hietala; Andreas Mårtensson; Billy Ngasala; Sabina Dahlström; Niklas Lindegårdh; Anna Annerberg; Zul Premji; Anna Färnert; Pedro Gil; Anders Björkman; Michael Ashton
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

4.  A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.

Authors:  Rose McGready; Saw Oo Tan; Elizabeth A Ashley; Mupawjay Pimanpanarak; Jacher Viladpai-Nguen; Lucy Phaiphun; Katja Wüstefeld; Marion Barends; Natthapon Laochan; Lily Keereecharoen; Niklas Lindegardh; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  PLoS Med       Date:  2008-12-23       Impact factor: 11.069

5.  Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Jonathan Mayito; Lillian Nabukeera; Rhoda Namakula; Harriet Mayanja-Kizza; Elly Katabira; Muhammad Ntale; Nadine Pakker; Mairin Ryan; Warunee Hanpithakpong; Joel Tarning; Niklas Lindegardh; Peter J de Vries; Saye Khoo; David Back; Concepta Merry
Journal:  J Antimicrob Chemother       Date:  2012-06-11       Impact factor: 5.790

6.  Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast.

Authors:  Steffen Borrmann; Philip Sasi; Leah Mwai; Mahfudh Bashraheil; Ahmed Abdallah; Steven Muriithi; Henrike Frühauf; Barbara Schaub; Johannes Pfeil; Judy Peshu; Warunee Hanpithakpong; Anja Rippert; Elizabeth Juma; Benjamin Tsofa; Moses Mosobo; Brett Lowe; Faith Osier; Greg Fegan; Niklas Lindegårdh; Alexis Nzila; Norbert Peshu; Margaret Mackinnon; Kevin Marsh
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

7.  Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Violet Okaba-Kayom; Harriet Mayanja-Kizza; Elly Katabira; Warunee Hanpithakpong; Nadine Pakker; Thomas P C Dorlo; Joel Tarning; Niklas Lindegardh; Peter J de Vries; David Back; Saye Khoo; Concepta Merry
Journal:  J Antimicrob Chemother       Date:  2012-02-08       Impact factor: 5.790

8.  A simple and precise method for quantitative analysis of lumefantrine by planar chromatography.

Authors:  Purnima Hamrapurkar; Mitesh Phale; Sandeep Pawar; Priti Patil; Mittal Gandhi
Journal:  Pharm Methods       Date:  2010-10

Review 9.  Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.

Authors: 
Journal:  BMC Med       Date:  2015-09-18       Impact factor: 8.775

10.  Quantification of Lumefantrine in Human Plasma Using LC-MS/MS and Its Application to a Bioequivalence Study.

Authors:  Satish G Pingale; Kiran V Mangaonkar
Journal:  J Pharm (Cairo)       Date:  2012-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.